SEARCH

SEARCH BY CITATION

References

  • 1
    Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:124.
  • 2
    WHO Collaborating Center for Surveillance, Epidemiology, and Control of Influenza, Bright R, Shay D et al. High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents--United States, 2005–06 influenza season. MMWR Morb Mortal Wkly Rep 2006; 55:4446.
  • 3
    U.S. Centers for Disease Control and Prevention (CDC). CDC Health Advisory: CDC issues interim recommendations for the use of influenza antiviral medications in the setting of oseltamivir resistance among circulating influenza A (H1N1) viruses, 2008–09 influenza season. Available at http://emergency.cdc.gov/HAN/han00279.asp (Accessed 22 September 2011).
  • 4
    Le MT, Wertheim HF, Nguyen HD et al. Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 virus in humans in northern Vietnam. PLoS ONE 2008; 3:e3339.
  • 5
    U.S. Centers for Disease Control and Prevention (CDC). Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009–2010 season. Available at http://www.cdc.gov/h1n1flu/recommendations.htm (Accessed 22 September 2011).
  • 6
    Baggs J, Gee J, Lewis E et al. The Vaccine Safety Datalink: a model for monitoring immunization safety. Pediatrics 2011; 127(Suppl 1):S45S53.
  • 7
    Coleman LA, Kieke B, Irving S et al. Comparison of influenza vaccine effectiveness using different methods of case detection: clinician-ordered rapid antigen tests vs. active surveillance and testing with real-time reverse-transcriptase polymerase chain reaction (rRT-PCR). Vaccine 2011; 29:387390.
  • 8
    U.S. Centers for Disease Control and Prevention (CDC). 2011–2012 influenza antiviral medications: summary for clinicians. Available at http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm (Accessed 22 September 2011).
  • 9
    Genentech. Tamiflu (oseltamivir phosphate) Capsules and for Oral Suspension [Package insert]. South San Francisco, CA: Genentech USA, Inc, 2011. Available at http://www.gene.com/gene/products/information/tamiflu/pdf/pi.pdf (Accessed 7 March 2012).
  • 10
    GlaxoSmithKline. Relenza (Zanamivir for Inhalation) [Package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2011, Available at http://us.gsk.com/products/assets/us_relenza.pdf (Accessed 7 March 2012).
  • 11
    Roche Laboratories, Inc. Roche Prioritizes Production of Tamiflu® 75 mg Capsules (oseltamivir phosphate) to Provide Alternative to Limited Supplies of Tamiflu® for Oral Suspension (Oseltamivir Phosphate) and Tamiflu® 30 mg and 45 mg Capsules. Nutley, NJ: Roche Laboratories, Inc, 2009. Available at http://www.gene.com/gene/products/information/tamiflu/pdf/TAMIFLU_Supply_letter_09_04_2009.pdf (Accessed 22 September 2011)
  • 12
    Ortiz JR, Kamimoto L, Aubert RE et al. Oseltamivir prescribing in pharmacy-benefits database, United States, 2004–2005. Emerg Infect Dis 2008; 14:12801283.
  • 13
    U.S. Department of Health and Human Services (HHS). HHS region map. Available at http://www.hhs.gov/about/regionmap.html. (Accessed 6 September 2011).
  • 14
    US Centers for Disease Control and Prevention (CDC). Swine influenza A (H1N1) infection in two children--Southern California, March–April 2009. MMWR Morb Mortal Wkly Rep 2009; 58:400402.
  • 15
    U.S. Centers for Disease Control and Prevention (CDC). Update: influenza activity – United States, August 30, 2009-March 27, 2010, and composition of the 2010–11 influenza vaccine. MMWR Morb Mortal Wkly Rep 2010; 59:423430.
  • 16
    Lee GM, Greene SK, Weintraub ES et al. H1N1 and seasonal influenza vaccine safety in the Vaccine Safety Datalink Project. Am J Prev Med 2011; 41:121128.
  • 17
    Marsden-Haug N, Foster VB, Gould PL, Elbert E, Wang H, Pavlin JA. Code-based syndromic surveillance for influenzalike illness by International Classification of Diseases, Ninth Revision. Emerg Infect Dis 2007; 13:207216.
  • 18
    Jain S, Kamimoto L, Bramley AM et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. N Engl J Med 2009; 361:19351944.
  • 19
    Louie JK, Acosta M, Winter K et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A (H1N1) infection in California. JAMA 2009; 302:18961902.
  • 20
    Rothberg MB, Haessler SD. Complications of seasonal and pandemic influenza. Crit Care Med 2010; 4(Suppl):e91e97.
  • 21
    Siston AM, Rasmussen SA, Honein MA et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA 2010; 303:15171525.
  • 22
    U.S. Food and Drug Administration (FDA). Emergency use of Tamiflu in infants less than 1 year of age. Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm183870.htm (Accessed 21 September 2011).
  • 23
    Jernigan DB, Lindstrom SL, Johnson JR et al. Detecting 2009 pandemic influenza A (H1N1) virus infection: availability of diagnostic testing led to rapid pandemic response. Clin Infect Dis 2011; 52(Suppl 1):S36S43.
  • 24
    Schatz M, Chambers CD, Jones KL, Louik C, Mitchell AA. Safety of influenza immunizations and treatment during pregnancy: the Vaccines and Medications in Pregnancy Surveillance System. Am J Obstet Gynecol 2011; 204:S64S68.
  • 25
    Baxter R. Surveillance lessons from first-wave pandemic (H1N1) 2009, Northern California, USA. Emerg Infect Dis 2010; 16:504506.
  • 26
    Schwab RS, England AC Jr, Poskanzer DC, Young RR. Amantadine in the treatment of Parkinson’s disease. JAMA 1969; 208:11681170.
  • 27
    Schapira M. Treating multiple sclerosis with amantadine hydrochloride. J R Coll Gen Pract 1974; 24:411412.
  • 28
    Donfrancesco R, Calderoni D, Vitiello B. Open-label amantadine in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007; 17:657664.
  • 29
    Lucetti C, Gambaccini G, Bernardini S et al. Amantadine in Huntington’s disease: open-label video-blinded study. Neurol Sci 2002; 23(Suppl 2):S83S84.